Alexion and Yale discover harmful complement activation in patients with acute coronary syndrome
NEW HAVEN, CONN, March 13, 2000 -- Scientists from Alexion Pharmaceuticals Inc. (Nasdaq: ALXN) and Yale University School of Medicine, both of New Haven, CT, today reported they have discovered that patients with acute coronary syndrome (ACS) have severe inflammation including significant production of injurious complement components in their coronary arteries. The report was made at the Scientif....NAGOYA, JAPAN, Oct. 25, 1999 -- Researchers from the Yale University School of.Medicine and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported that.transplanting genetically modified pig cells into surgically damaged spinal.cords of non-human primates can regenerate the myelin sheath around the injured.fragment of the spinal cord. Alexion believes that these results represent a.critic....MIAMI BEACH, FL, Oct. 25, 1999 -- Researchers from the Harvard Medical School.and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported that the.transplantation of immunoprotected pig neurons into non-human primate models of.Parkinson's disease resulted in successful engraftment and function of the.transplanted cells. Presented here at the 29th Meeting of the Society for.Neuroscience, th...